We extend our sincerest thanks to all who have supported our team and company during these pivotal weeks. As 2024 approaches, we are filled with optimism for the future journeys of our talented team and the ongoing advancements in the gene therapy field. Wishing you all a joyful holiday season and a prosperous 2024 with a heartfelt farewell from Locanabio. ?
Locanabio, Inc.
生物技术研究
San Diego，California 5,291 位关注者
Creating RNA-targeting gene therapies to treat devastating diseases
关于我们
At Locanabio, we are developing a new class of genetic medicines that has the potential to significantly improve the lives of patients with devastating genetic diseases by correcting the message of disease-causing RNA. Our proprietary platform uses gene therapy to deliver RNA-binding systems, including snRNA, Cas13d and PUF, that can be engineered to selectively manipulate disease-causing RNA by multiple mechanisms. Our systems are designed to provide a durable therapy with a single administration without altering a cell’s DNA. Locanabio’s platform has applications across a range of tissues and diseases, and we are currently advancing programs in rare genetic neuromuscular and neurodegenerative diseases. With world leadership in RNA biology and RNA-mediated disease and a top tier Board of Directors and panel of Scientific Advisors, we are poised to develop the next generation of genomic medicines for functional correction of disease.
- 网站
-
https://www.locanabio.com
Locanabio, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- San Diego，California
- 类型
- 私人持股
- 创立
- 2016
地点
-
主要
获取路线
US，California，San Diego，92121
Locanabio, Inc.员工
-
Jeffrey Ostrove
Co-founder and Director, Papillon Therapeutics
-
Anthony Ramirez
Director, Gene Therapy Process Development at Locanabio, Inc.
-
Oscar Diago
Research Scientist at Locanabio, Inc
-
Ronald Torres
Histologist with 15+ years leveraging immunohistochemistry, ISH, microscopy/digital pathology/image analyses in preclinical drug discovery, biomarker…